Monday 20 April 2015 at 15:16

Melanoma drug may help lung cancer patients

Merck & Co is applying to have its drug Keytruda approved in the United States as a treatment for advanced non-small cell lung cancer, the most common form of the disease.

Keytruda, also known as pembrolizumab, is already approved by the country’s Food & Drug Administration (FDA) for patients with advanced melanoma who are no longer responding to other therapies.

It was shown in a trial to shrink tumours in nearly half of advanced lung cancer patients with high levels of a protein called PD-1, or a related target known as PD-L1, which is used by tumours to evade the body's own disease-fighting cells.

Merck said its FDA lung cancer application is for patients with both squamous and non-squamous NSCLC.

The results were presented at a meeting of the American Association for Cancer Research and published in the New England Journal of Medicine.



Was this helpful?   
Yes (49)
No (51)
Contact us
Call us now 0333 323 7200